Moxifloxacin-Bromfenac Solution (Imprimis) – sub-potent drug (2023)
Class III: A situation in which use of, or exposure to, a violative product is not likely to cause adverse health consequences
Class III recall indicates unlikely adverse health consequences.
This AI-generated summary is provided for general informational purposes only and is derived from publicly available recall notices. It supplements but does not replace official agency classifications or safety instructions.
Check Your Product
According to the U.S. Food and Drug Administration (FDA)
Product
Moxifloxacin - Bromfenac Sterile Ophthalmic Solution 0.5% / 0.075%, 5mL bottle, Imprimis NJOF, LLC. 1705 Route 46 West, Unit 6B, Ledgewood, NJ 07852 (844)-446-6979, NDC: 71384-311-05.
Brand
Imprimis NJOF, LLC
Lot Codes / Batch Numbers
Lot #s: 22DEC047 exp 9/16/23, 23FEB057 exp 11/24/23.
Products Sold
Lot #s: 22DEC047 exp 9/16/23, 23FEB057 exp 11/24/23.
Imprimis NJOF, LLC is recalling Moxifloxacin - Bromfenac Sterile Ophthalmic Solution 0.5% / 0.075%, 5mL bottle, Imprimis NJOF, LLC. due to Subpotent Drug; sub-potent Bromfenac levels, below the 90.0-110.0% specification range.. This is a Class I recall, indicating a high risk of serious health consequences. Based on FDA drug enforcement report.
Summary derived from FDA notice
Reason for Recall
As stated by FDA
Subpotent Drug; sub-potent Bromfenac levels, below the 90.0-110.0% specification range.
Recommended Action
Per FDA guidance
Consumers should stop using the product and contact the recalling firm, their healthcare provider, or return it to the place of purchase.
Verify this information on the official source
For complete details and official instructions, check the U.S. Food and Drug Administration (FDA) directly.
View official FDA recall noticePage updated: Jan 7, 2026